Results 191 to 200 of about 1,575,012 (307)
Intercompartmental communication in senescence
Senescent cells experience structural changes in the plasma membrane, endoplasmic reticulum, mitochondria, lysosomes, nucleus, and cytoskeleton. These alterations disrupt crosstalk among cellular compartments, impairing vesicular trafficking, contact sites, and molecular flow.
Krystyna Mazan‐Mamczarz +3 more
wiley +1 more source
Persistent COVID-19 Pneumonia in a Patient on Rituximab. [PDF]
Clarke K, Naidu S, Wan C, Stampfer S.
europepmc +1 more source
A novel signature integrating genome‐wide analysis with clinical factors predicts recurrence in stage II colorectal cancer and enables a new risk stratification to guide postoperative adjuvant chemotherapy. Clinical risk stratification for postoperative recurrence in patients with pathological stage II (pStage II) colorectal cancer (CRC) is essential ...
Mayuko Otomo +7 more
wiley +1 more source
Report on the 10th Asia-Oceania Mass Spectrometry Conference (AOMSC2025). [PDF]
Ishihama Y.
europepmc +1 more source
Natural products target the aging kidney in diabetic nephropathy by restoring the AMPK–SIRT1–Nrf2 axis, reducing oxidative stress, inflammation, fibrosis, and cellular senescence while enhancing mitochondrial biogenesis and antioxidant defenses.
Sherif Hamidu +8 more
wiley +1 more source
From AIBO to robosphere. Organizational interdependencies in sustainable robotics. [PDF]
Fleres A, Damiano L.
europepmc +1 more source
ABSTRACT As global populations age, cancer is increasingly becoming a leading cause of morbidity and mortality among older adults, particularly in low‐ and middle‐income countries (LMICs). Despite accounting for the majority of new cancer cases and deaths, older individuals remain underrepresented in cancer research, clinical guidelines, and health ...
Ibrahim Bidemi Abdullateef +2 more
wiley +1 more source
Intravascular organizing thrombus in the forearm: a unique imaging presentation. [PDF]
Bass R +5 more
europepmc +1 more source
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source

